A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs ITI 214 (Primary)
- Indications Cognition disorders; Heart failure; Parkinson's disease
- Focus Pharmacodynamics
- Sponsors Intra-Cellular Therapies
- 05 Nov 2019 According to a Intra-Cellular Therapies media release, data fromt this trial is expected later this year.
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 27 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.